Pharma Mar (PHMMF) Stock Price, News & Analysis

Company Overview

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Key Stats

• Today's Range: $88.18 to $88.18
• 50-Day Range: $88.18 to $105.60
• 52-Week Range: $26.85 to $105.60
• Volume: N/A
• Average Volume: 1,297 shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Buy

Pharma Mar Stock Analysis - MarketRank™

Pharma Mar scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pharma Mar.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Pharma Mar has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.22% of the float of Pharma Mar has been sold short.

Short Interest Ratio / Days to Cover

Pharma Mar has a short interest ratio ("days to cover") of 396, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharma Mar has recently increased by 21.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharma Mar does not currently pay a dividend.

Dividend Growth

Pharma Mar does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.22% of the float of Pharma Mar has been sold short.

Short Interest Ratio / Days to Cover

Pharma Mar has a short interest ratio ("days to cover") of 396, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharma Mar has recently increased by 21.10%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Pharma Mar has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pharma Mar this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharma Mar insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.88% of the stock of Pharma Mar is held by insiders.

PHMMF Stock Analysis - Frequently Asked Questions

How have PHMMF shares performed this year?

Pharma Mar's stock was trading at $81.07 at the beginning of 2025. Since then, PHMMF stock has increased by 8.8% and is now trading at $88.1830.
View the best growth stocks for 2025 here.

How do I buy shares of Pharma Mar?

Shares of PHMMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 5/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PHMMF
• Previous Symbol: NASDAQ:PHMMF
• CIK: N/A
• Web: www.pharmamar.com
• Phone: (491) 846-6000
• Fax: 34-91-846-6001
• Employees: 509
• Year Founded: 1986

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 2.55
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: $171.15 million
• Price / Sales: 9.28
• Cash Flow: $0.38 per share
• Price / Cash Flow: 231.27
• Book Value: $11.62 per share
• Price / Book: 7.59

Miscellaneous

• Outstanding Shares: 18,010,000
• Free Float: N/A
• Market Cap: $1.59 billion
• Optionable: Not Optionable
• Beta: 0.29